Comparative Pharmacology
Head-to-head clinical analysis: CINACALCET HYDROCHLORIDE versus PARSABIV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CINACALCET HYDROCHLORIDE versus PARSABIV.
CINACALCET HYDROCHLORIDE vs PARSABIV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Allosteric activator of the calcium-sensing receptor (CaSR) on parathyroid chief cells, increasing sensitivity to extracellular calcium and reducing parathyroid hormone (PTH) secretion.
Calcium-sensing receptor (CaSR) agonist; increases the sensitivity of the CaSR to extracellular calcium, thereby decreasing parathyroid hormone (PTH) secretion.
30 mg orally once daily, titrate every 2-4 weeks to a maximum of 180 mg once daily to achieve target intact parathyroid hormone (iPTH) level.
Initial dose 5 mg intravenously three times per week, titrated by 2.5 or 5 mg increments every 4 weeks to a maximum of 15 mg three times per week to achieve target parathyroid hormone levels.
None Documented
None Documented
Terminal elimination half-life: 30–40 hours in patients with normal renal function; prolonged to 42–83 hours in moderate to severe hepatic impairment. Steady-state reached within 7 days.
Terminal elimination half-life of 3-5 days, supporting once-weekly subcutaneous dosing.
Renal: 80% (as metabolites), Fecal: 15%, Biliary: negligible.
Renal: negligible (<2% unchanged); fecal: primary route via biliary elimination of intact drug and metabolites; not dialyzable.
Category C
Category C
Calcimimetic
Calcimimetic